Brokers Offer Predictions for Evommune FY2027 Earnings

Evommune, Inc. (NYSE:EVMN) – Investment analysts at HC Wainwright issued their FY2027 EPS estimates for Evommune in a research note issued to investors on Wednesday, March 18th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($3.30) per share for the year. HC Wainwright has a “Buy” rating and a $50.00 price target on the stock.

Several other equities research analysts have also weighed in on the company. Leerink Partners started coverage on Evommune in a report on Monday, December 1st. They issued an “outperform” rating and a $42.00 target price for the company. William Blair started coverage on Evommune in a report on Monday, December 1st. They set an “outperform” rating on the stock. The Goldman Sachs Group raised shares of Evommune to a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada upgraded shares of Evommune to a “moderate buy” rating in a research note on Tuesday, March 10th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $54.00 price objective on shares of Evommune in a report on Wednesday, February 18th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $47.17.

Evommune Stock Performance

Shares of NYSE EVMN opened at $23.35 on Thursday. The firm has a market cap of $840.99 million and a price-to-earnings ratio of -2.89. The firm’s 50-day moving average is $23.32. Evommune has a 52 week low of $13.89 and a 52 week high of $33.20.

Evommune (NYSE:EVMN) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.61).

Institutional Trading of Evommune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new stake in Evommune in the 4th quarter valued at approximately $34,000. The Manufacturers Life Insurance Company acquired a new position in shares of Evommune during the fourth quarter worth approximately $179,000. XTX Topco Ltd bought a new stake in shares of Evommune in the fourth quarter valued at approximately $321,000. Oxford Asset Management LLP bought a new stake in shares of Evommune in the fourth quarter valued at approximately $335,000. Finally, State Street Corp acquired a new stake in shares of Evommune in the fourth quarter worth $539,000.

Key Headlines Impacting Evommune

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: Clear Street / Clear Str initiated coverage / upgraded Evommune with a buy / strong-buy stance, which can attract demand from momentum and growth-focused funds. Clear Street initiates coverage of Evommune (EVMN) with buy recommendation
• Neutral Sentiment: A market/industry article about Planet Labs was also logged in the feed but is unrelated to Evommune’s fundamentals or near-term catalysts. Traders are unlikely to move EVMN based on that piece. Planet Labs (NYSE:PL) Revenue Beats, Lags NYSE Index on Profit
• Negative Sentiment: HC Wainwright sharply cut its quarterly and full-year EPS forecasts for 2026–2027 (FY2026 EPS from prior -$1.40 to -$3.00; FY2027 -$3.30) while keeping a “Buy” rating and $50 price target. The large downward revisions signal higher expected cash burn or slower progress on clinical/commercial milestones, which is a clear near-term negative for valuation and could pressure the stock despite the buy rating. HC Wainwright Issues Pessimistic Forecast for Evommune (NYSE:EVMN) Stock Price
• Negative Sentiment: Additional outlets reported Clear Str/other firms’ upgrades (e.g., Zacks/TickerReport) but these are outweighed by the magnitude of HC Wainwright’s downward EPS revisions; the net effect today appears to be defensive selling and profit-taking. TickerReport coverage of Clear Str upgrade

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.